Product & Industry News
Drug Discovery World
My Personal Therapeutics and Pentavere scoop funding for lung cancer digital therapeutics

My Personal Therapeutics and Pentavere scoop funding for lung cancer digital therapeutics

3 July 2020
Image: Japeth Mast

My Personal Therapeutics and Pentavere Research Group, have achieved EUREKA Collaborative R&D: AI and Quantum Technologies Competition success for their project Utilisation of AI to develop Personalised Treatment Plans for cancer.

Funding totalling £792,000 is co-funded by the UK’s innovation agency, Innovate UK, and Canada’s National Research Council’s Industrial Research Assistant Program, as part of their Collaborate R&D programme. These funds will be used by Pentavere Research Group and My Personal Therapeutics to access Genomics England’s whole genome sequencing lung cancer data set and selectively generate drosophila avatars for high-throughput drug screening. The resulting tumour genomic profile and corresponding drug treatment recommendation data will feed into the AI Personal Discovery Process predictive model. Potentially, some of the funding can support personalised treatment recommendations for lung cancer patients in the UK. 

"This Eureka award will partly fund this ground-breaking collaboration between My Personal Therapeutics, Pentavere and Genomics England towards the development of our rapid personalised cancer therapeutics offering – AI PDP, " said My Personal Therapeutics’ CEO Laura Towart.

My Personal Therapeutics is a London based medtech/digital therapeutics company offering personalised cancer therapeutics utilising technology developed at Mt Sinai Medical Center. The Personal Discovery Process technology leverages Big Data curated from electronic health records, and genomics to build personalised fruit fly ‘avatars’ that model individual patients at an unprecedented level of complexity. Using robotics, thousands of drugs are screened in combinations to identify drug cocktails designed to target the tumour while preserving the patient’s quality of life. Nearly all combinations incorporate non-cancer drugs, making them less toxic and more affordable. We are integrating AI/ predictive modeling to enable rapid personalised treatment recommendations.